Best Magazine for Pharma Industry Leaders

      Pharma Focus Asia magazine is one of the best pharma magazines in Asia.  Our Magazine features articles about the latest pharmaceutical industry technologies & developments and covering manufacturing, clinical trials, research and development, strategy, Information technology and more!             

[pharmafocusasiamagazine]

The authors Ravi Iyer, Visionary and Innovative Executive & Narasimha, Result-driven Leader shared their views with Pharma Focus Asia.

Today, engaging patients by merely sending emails, messages, phone calls, or through mobile apps is completely outdated. The journey involves: enhancing the user experience by boosting efficiency, speed, accuracy, and strategy. The acceleration of AI-powered self-service tools in the PBM industry, especially during COVID-19, has created overwhelming demand-led innovation to help patients collaborate seamlessly with their payers, providers, and pharmacies.

 Find out more info here- https://www.pharmafocusasia.com/articles/5-proven-ways-to-take-pbms-to-the-future-today-with-conversational-ai

[pharmafocusasiamagazine]

Role of miRNAs in Neurodegeneration Diseases

Bidisha Roy, Department of Biological Sciences, Rutgers University shared her views with Pharma Focus Asia.

This article highlights the relevance of studying brain-enriched miRNAs, the mechanisms underlying their regulation of target gene expression, their dysregulation leading to progressive neurodegeneration, and their potential for biomarker marker and therapeutic intervention. This article has been written to emphasize ways for the effective diagnosis and prevention of these neurodegenerative disorders in the near future.

Neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), and Amyotrophic lateral sclerosis (ALS) are a group of age-related progressive disorders initiated by the neuronal loss that eventually leads to cognitive and movement disorders. These diseases are thought to be caused by alterations to protein-coding genes. Non-coding RNAs participate in translational regulation and comprise 95 per cent of total human cellular RNAs.

Read More: https://www.pharmafocusasia.com/research-development/role-mirnas-neurodegeneration

[pharmafocusasiamagazine]

Why we need to prevent antifungal resistance?- Pharma Focus Asia

L Shamithra M Sigera and David W Denning from University of Manchester shared their views with Pharma Focus Asia on “Anti-Fungal Resistance”.

Anti-fungal resistance is increasing, with the global spread of the multi-drug resistant Candida auris since 2008, increasing rates (up to 95 per cent) of azole resistance in Aspergillus fumigatus and the emergence of a new species of Trichophyton in India which is terbinafine resistant. Accurate and rapid diagnosis of most fungal infections is now possible with nonculture based tests, allowing tailoring of both antibacterial and anti-fungal therapy, but culture and susceptibility testing are required to detect resistance. New anti-fungal agents are being developed, but not fast enough to address this problem without minimising empirical anti-fungal therapy in patients and reduction in azole fungicides in crops.

For more info visit:

https://www.pharmafocusasia.com/research-development/anti-fungal-resistance

[pharmafocusasiamagazine]

Maurizio Luongo, CEO, A. Menarini Asia-Pacific Holdings Pte Ltd. (Menarini Asia-Pacific) shared his views with Pharma Focus Asia on “Building a Biomedical Diagnostic Research Hub in Asia”.

Why the need to launch a biomarker research arm?

Menarini Biomarkers (A. Menarini Biomarkers Singapore Pte Ltd) was founded with the mission of identifying, developing, and validating new biomarkers on circulating human cells for applications in diagnostics.

There is a current healthcare gap in precision medicine surrounding the fields of early disease prediction and disease control, particularly related to precision rare-cell isolation, analysis, and disease diagnosis. Menarini Biomarkers uses single-cell analysis to provide clinicians with new tools for early detection, tracking disease progression, and the measurement of real-time responses to innovative therapies.

The R&D team specialises in pathogenic single-cell isolation that enables scientists to pinpoint specific disease markers, also known as biomarkers. The identification and selection of pathogenic single cells from blood samples is incredibly useful in disease treatment, as it helps healthcare practitioners narrow therapies down to target cells.

Read More : https://www.pharmafocusasia.com/research-development/building-biomedical-diagnostic-research

[pharmafocusasiamagazine]

Neglected tropical diseases (NTDs) affect more than one billion people worldwide. Although this group of 20 infectious conditions corresponds to 11 per cent of the global disease burden, no innovative drugs have been developed in this field. The World Health Organization (WHO) has played a central role in raising global awareness on the subject. Recently, WHO launched its roadmap on NTDs for 2021-2030, which highlights the advances made over the past years and sets the strategies to eliminate these diseases by 2030. According to this agenda, pharmaceutical innovation will be central for the achievement of the agreed goals, especially for protozoan and helminthic NTDs. Unfortunately, drug research and development (R&D) for highly prevalent NTDs such as schistosomiasis, human African trypanosomiasis, Chagas disease and leishmaniasis, has, for  decades, been characterised for insufficient funding and low-technology approaches. This paradigm has recently changed given the rising of initiatives that involve notfor- profit organisations, universities, and pharma companies. Among these partnerships we can cite the NTD Drug Discovery Booster, the Lead Optimization Latin America (LOLA),the WIPO Re: Search project, and the Welcome Trust for NTD drug discovery programme, the first two being administered by the Drugs for Neglected Diseases initiative (DNDi). These programmes have proven invaluable to catalyse drug R&D for NTDs by integrating medicinal chemistry and parasite biology and allowing multi-parameter optimisation (MPO) of high-quality hits and lead compounds. Despite these efforts, innovative products have not been regularly developed and approved for NTDs. The few products that have recently been approved for  these conditions are known or repurposed drugs, new formulations, or combination chemotherapies.

Read More: https://www.pharmafocusasia.com/research-development/innovation-elimination-neglected

[pharmafocusasiamagazine]

Genetic testing can be used to reduce the risk of experiencing adverse reactions. Seldom is one single gene responsible for altering a drug’s benefitrisk balance. This is more often due to multiple genetic and non-genetic factors, thus increasing the complexity and limiting the utility of a widespread use of pharmacogenomics. Widespread use of genotyping and artificial intelligence can overcome these limits.

Pharmacogenomics is the study of the genes, their structure, function, polymorphisms, transcription, and translation, how they interact with each other and with environment. The main goal of pharmacogenomics is to understand how genetic variants can alter a drug’s benefit-risk balance. Genetic differences that are likely to be of most relevance to drugs and that can alter their benefit-risk balance pertain to four broad categories.

Read More: https://www.pharmafocusasia.com/research-development/pharmacogenomic-information

[pharmafocusasiamagazine]

Operational excellence (OPEX) is the philosophy summarising numerous technical and social practices aiming at improving operations. However, the complexity of the practices and multiplicity of the initiatives hinders to always identify and set the most promising priorities. Being able to take decisions based on data and measured situations can improve the efficacy of the strategic initiatives. The St. Gallen manufacturing and quality control (QC) benchmarking programmes support pharmaceutical companies with a rich base of information needed to inform their decision making processes.

This article discusses two practical examples of how data driven improvements can be initiated and derived from a benchmarking. Firstly, an example from the manufacturing and OPEX benchmarking is presented. Secondly, a project that emerged based on QC lab benchmarking results is illustrated and discussed. Finally, the benefits of data driven decision are highlighted.

Authors: Matteo Bernasconi, Research Associate, University of St.Gallen

Gian-Andri Steiger, Research Associate, University of St.Gallen

Marten Ritz, Post-doctoral Researcher, University of St.Gallen

Thomas Friedli, Director, Institute of Technology Management

For more info visit: https://www.pharmafocusasia.com/manufacturing/learn-from-metrics .

[pharmafocusasiamagazine]

Adrija Hajra, Internal Medicine Physician, currently affiliated with Montefiore Medical Center/Albert Einstein College of Medicine, shared her views with Pharma Focus Asia on “Recent Advances and Future Prospects of Treatment of Pulmonary Hypertension”.

Pulmonary hypertension is defined as increase in pressure of the blood vessels of the lungs. The mechanism of developing pulmonary hypertension is complex. Recently it has been noted that COVID-19-affected patients are at risk of having pulmonary hypertension. There are already multiple available treatments for this condition. In addition, recent advancements are going on in the treatment of pulmonary hypertension.

Currently, there are several therapeutic options available. But there are drugs under trial, and they are presently being evaluated for PHTN treatment. In addition, the recent coronavirus infection 2019 (COVID-19) pandemic has initiated a new interest in PHTN management among health care providers. COVID-19infection has been shown to worsen pre-existing PHTN. COVID-19 is also anticipated to be a significant etiology of PHTN in the coming years due to the long-term sequala of lung fibrosis associated with the infection.

For More Info Visit: https://www.pharmafocusasia.com/manufacturing/prospects-treatment-pulmonary-hypertension

[pharmafocusasiamagazine]

The SARS-CoV-2 pandemic has required the development of new methods for rapidly developing effective vaccines and drugs to treat COVID- 19 patients. There are approximately 12,000 existing drugs, approved natural products, and clinical trials candidates whose safety in man has already been established. Computational repurposing of these drugs, where mathematical methods are used to simulate their interactions with key proteins in the virus, is a rapid way to find new treatments for SARS-CoV-2.

For more info visit: https://www.pharmafocusasia.com/research-development/computational-repurposing-drugs

[pharmafocusasiamagazine]

Rajendra Talele,Pharmaceutical Professional, shared his opinion with Pharma Focus Asia on “Outsourcing Clinical Trials”.

Clinical Trials are an integral part of drug development and are often outsourced to third parties clinical research organisations (CROs) for execution. The selection of a CRO for a trial is usually based on certain parameters. An experienced CRO can complete the trials smoothly, while a non-experienced CRO may worry the sponsor. All CROs are good but not necessarily all are experienced and capable to handle your specific trial requirements, even your preferred CRO.

Any negligence in trial design, planning, or conduct jeopardises the outcome of the trial results. Therefore, the selection of a CRO or an outsourcing partner is critical and challenging.

For More info visit:

https://www.pharmafocusasia.com/clinical-trials/outsourcing-clinical-trials

[pharmafocusasiamagazine]

Ben Wylie, Senior Product Manager, ChargePoint Technology shared his views with Pharma Focus Asia on "Pharma Consumables Supply Chain".

In this article, Ben offers pharma company procurement teams three top tips to finding a trusted consumables supplier to ensure the security and integrity of their supply chain. The author offers advice on questions to ask suppliers, including suppliers of single-use manufacturing equipment, to ensure that they are satisfied that their partners can continue to deliver material when they need it. The author Ben Wylie, highlights the steps ChargePoint Technology has taken to ensure that they remain a reliable and trusted partner even during these unprecedented times.

For more information visit: https://www.pharmafocusasia.com/strategy/pharma-consumables-supply-chain

[pharmafocusasiamagazine]

DuoSet ELISA Development Systems

DuoSet™ ELISA Development Systems kits offer a reliable, economical alternative to purchasing a ready-to-use ELISA or separate antibodies. Each DuoSet kit contains carefully selected and validated matched antibody pairs for accurate measurement of recombinant and natural proteins in biological fluids. Visit:  http://track.pharmafocusasia.com/202208250848361758266899/

[pharmafocusasiamagazine]

Bio-Techne - Simple Plex™ Automated Immunoassays:

Single and multiplex automated immunoassays get you data in 90 minutes. Simple Plex assays are consistently reproducible across users. The fully automated Ella system offers an attractive alternative to traditional plate-based ELISAs. Learn More: https://lnkd.in/gAqEWp7u

[pharmafocusasiamagazine]

Hisham Al-Obaidi, Thermal analysis Lead, University of Reading shared his views with Pharma Focus Asia on "The Use of Crystal Engineering to Effectively Target Lung Infections".

Crystal engineering offers novel solutions for the delivery of antimicrobials to treat lung infections. This approach is based on removing the need for carrier particles allowing larger doses of the drug to be delivered.

Read More: https://www.pharmafocusasia.com/manufacturing/crystal-engineering-target-lung-infections

For latest magazine visit: https://www.pharmafocusasia.com/magazine-subscription

[pharmafocusasiamagazine]

Environmental and Sustainability Requirements in Drug Procurement- Pharma Focus Asia

Josep M Guiu, Director, Pharmacy and Medicines, Faculty of Pharmacy and Food Sciences, University of Barcelona shared his views with Pharma Focus Asia on "ENVIRONMENTAL AND SUSTAINABILITY REQUIREMENTS IN DRUG PROCUREMENT".Drug assessment is now progressively taking sustainability criteria into account alongside traditional cost-effectiveness, for their procurement, pricing, and reimbursement policies for pharmaceuticals. Many pharma companies have effectively incorporated innovative actions in their production, consumption, and supply chain to improve environmental and social sustainability practices, and to address the UN’s Sustainable Development Goals. In Europe, there is an increasing trend of the inclusion of environmental, social, and governance issues along with quality and pricing in the decision-making process specifically with respect to tenders and procurement.

For more info visit: https://www.pharmafocusasia.com/research-development/environmental-sustainability-requirements-drug-procurement

#Environmental #SustainabilityRequirements #DrugProcurement  #PharmaArticles #PharmaIndustryUpdates

[pharmafocusasiamagazine]

Daphne Teo, CEO and Founder of NSG BioLabs, shares her insights & understanding of the innovative biotech ecosystem in Singapore & Asia. She elaborates on the opportunities for biotech startups and the kind of support they need to solve some of the biggest medical challenges of the 21st century. 

Read More: https://www.pharmafocusasia.com/expert-talk/innovative-biotech-ecosystem-singapore-asia

[pharmafocusasiamagazine]

A Digitalised Future for Pharmacovigilance- Pharma Focus Asia

The use of traditional paper-based case record forms (CRFs) are becoming a thing of the past as Contract research organisations (CROs) increasingly embrace digital transformation, enabling more accuracy and reliability of data, security in #pharmacovigilance, collaboration, innovation, and speed of operations.

The Future of Pharmacovigilance:

The shift to a digital-first economy continues to drive the need for digital transformation – essential to avoid being disrupted, and to remain competitive. Pharmaceutical organisations that have yet to take the step toward digital transformation should now plan for and lay the groundwork for digital PV processes. 

Read More: https://pharmafocusasia.com/information-technology/digitalised-future-pharmacovigilance

#pharmaarticles #pharmaindustryupdates #pharmaceuticalupdates #digitaltransformation